AtriCure (ATRC) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
465.3M
Gross Profit
347.5M
74.69%
Operating Income
-40.0M
-8.60%
Net Income
-44.7M
-9.61%
Balance Sheet Metrics
Total Assets
609.3M
Total Liabilities
148.4M
Shareholders Equity
461.0M
Debt to Equity
0.32
Cash Flow Metrics
Operating Cash Flow
9.5M
Free Cash Flow
-11.3M
Revenue & Profitability Trend
AtriCure Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 465.3M | 399.2M | 330.4M | 274.3M | 206.5M |
| Cost of Goods Sold | 117.8M | 98.9M | 84.4M | 68.5M | 57.2M |
| Gross Profit | 347.5M | 300.4M | 245.9M | 205.9M | 149.3M |
| Operating Expenses | 387.5M | 327.1M | 288.6M | 253.2M | 193.9M |
| Operating Income | -40.0M | -26.7M | -42.7M | -47.3M | -44.6M |
| Pre-tax Income | -43.7M | -29.8M | -46.2M | 50.4M | -48.0M |
| Income Tax | 1.0M | 591.0K | 268.0K | 188.0K | 114.0K |
| Net Income | -44.7M | -30.4M | -46.5M | 50.2M | -48.2M |
| EPS (Diluted) | - | -$0.66 | -$1.02 | $1.09 | -$1.14 |
Income Statement Trend
AtriCure Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 267.8M | 266.2M | 215.2M | 196.1M | 306.7M |
| Non-Current Assets | 341.5M | 347.7M | 370.2M | 419.2M | 407.8M |
| Total Assets | 609.3M | 613.9M | 585.4M | 615.3M | 714.5M |
| Liabilities | |||||
| Current Liabilities | 73.4M | 74.6M | 58.4M | 56.4M | 49.1M |
| Non-Current Liabilities | 74.9M | 73.2M | 70.3M | 75.1M | 253.0M |
| Total Liabilities | 148.4M | 147.8M | 128.7M | 131.6M | 302.1M |
| Equity | |||||
| Total Shareholders Equity | 461.0M | 466.2M | 456.8M | 483.8M | 412.4M |
Balance Sheet Composition
AtriCure Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -44.7M | -30.4M | -46.5M | 50.2M | -48.2M |
| Operating Cash Flow | 9.5M | -7.7M | -20.7M | -106.8M | -16.2M |
| Investing Activities | |||||
| Capital Expenditures | -11.4M | -12.0M | -16.9M | -9.8M | -5.3M |
| Investing Cash Flow | 42.2M | 51.8M | 44.0M | 23.5M | -156.2M |
| Financing Activities | |||||
| Dividends Paid | 0 | - | - | - | - |
| Financing Cash Flow | -8.6M | -7.6M | -13.1M | -20.0M | 175.2M |
| Free Cash Flow | -11.3M | -37.5M | -39.0M | -23.5M | -25.1M |
Cash Flow Trend
AtriCure Key Financial Ratios
Valuation Ratios
Forward P/E
-50.41
Price to Book
3.46
Price to Sales
3.28
PEG Ratio
-50.41
Profitability Ratios
Profit Margin
-7.95%
Operating Margin
-4.82%
Return on Equity
-8.38%
Return on Assets
-3.70%
Financial Health
Current Ratio
4.11
Debt to Equity
17.03
Beta
1.60
Per Share Data
EPS (TTM)
-$0.81
Book Value per Share
$9.19
Revenue per Share
$10.19
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| atrc | 1.6B | - | 3.46 | -8.38% | -7.95% | 17.03 |
| Intuitive Surgical | 189.7B | 77.39 | 11.09 | 15.96% | 28.41% | 0.00 |
| Becton, Dickinson | 50.0B | 33.87 | 1.98 | 5.89% | 7.18% | 76.34 |
| Lemaitre Vascular | 1.9B | 42.77 | 5.48 | 13.77% | 19.96% | 53.33 |
| Azenta | 1.5B | -10.80 | 0.90 | -8.58% | -9.77% | 3.16 |
| Pulse Biosciences | 1.1B | -18.29 | 9.24 | -77.86% | 0.00% | 7.24 |
Financial data is updated regularly. All figures are in the company's reporting currency.